Ping Cao


Dr. Cao is the Co-founder and CEO at BridGene Biosciences, Inc. He has 18+ years of biopharma industry experience in both large and small molecule drug discovery research. He is an expert in biophysical/biochemical characterization of proteins/peptides, focusing on leveraging mass spectrometry to support the biopharmaceutical pipeline. His teams have helped advance multiple programs into the clinic in a variety of disease indications, including diabetes, obesity, dyslipidemia,and cardiovascular disease.

Dr. Cao has held various managerial positions throughout his career. He was responsible for establishing a state-of-the-art mass spectrometry and analytical group at Tularik, Inc., which was acquired by Amgen in 2004. Most recently, Dr. Cao was a Principal Scientist in the Discovery Analytical Attributes Group at Amgen, Inc. His group engaged in hypothesis-driven targeted proteomics to complement Amgen’s genetic discovery platform, with the goal of facilitating seamless and rapid advancement of projects from research to commercialization.

Dr. Cao received his Ph.D. from the University of Texas at Austin in Analytical Chemistry and did his Postdoctoral fellowship at Genentech, Inc. He also holds an M.S. in Chemical Engineering from SINOPEC Research Institute of Petroleum Processingin China, as well as a B.S. in Physical Chemistry from Shandong University in Jinan, China.